A single-segment structure focused on pharmaceutical research and development
First written in FY2017-Q3. 14 of 16 entries say "Restated". Latest entry: FY2026-H1.
10 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「The operating results by segment are as follows.」
Disclosure continues to be presented across two reportable segments: pharmaceutical research and development-related business and cancer precision medicine-related business. - FY2023-Q3RestatedAnnual report
「The operating results by segment are as follows.」
Disclosure continues to be presented across two reportable segments: pharmaceutical research and development-related business and cancer precision medicine-related business. - FY2023-Q1RestatedAnnual report
「The operating results by segment are as follows.」
Disclosure continues to be presented across two reportable segments: pharmaceutical research and development-related business and cancer precision medicine-related business. - FY2022-Q3RestatedAnnual report
「Our group’s principal businesses are “pharmaceutical research and development and related businesses” and “cancer precision medicine-related business.”」
Disclosure continues to be presented across two reportable segments: pharmaceutical research and development-related business and cancer precision medicine-related business. - FY2022-Q1RestatedAnnual report
「Through a capital and business alliance with Theragen Bio Co., Ltd. (headquartered in South Korea; “TB”; formerly Theragen Etex Co., Ltd.), which provides global next-generation sequencing analysis services for genomes, transcriptomes and epigenomes, we established Cancer Precision Medicine Co., Ltd. (“CPM”) as a subsidiary conducting large-scale genetic testing of cancer genes and research and development into cancer immunotherapy. CPM operates a cancer precision medicine-related business.」
Disclosure continues to be presented across two reportable segments: pharmaceutical research and development business and cancer precision medicine-related business. - FY2021-Q3RestatedAnnual report
「The operating results by segment are as follows.」
Disclosure continues to be presented across two reportable segments: pharmaceutical research and development-related business and cancer precision medicine-related business. - FY2021-Q2RestatedAnnual report
「The operating results by segment are as follows.」
Disclosure continues to be presented across two reportable segments: pharmaceutical research and development-related business and cancer precision medicine-related business. - FY2021-Q1RestatedAnnual report
「The operating results by segment are as follows.」
Disclosure continues to be presented across two reportable segments: pharmaceutical research and development-related business and cancer precision medicine-related business. - FY2020-Q3RestatedAnnual report
「The operating results by segment are as follows.」
Disclosure continues to be presented across two reportable segments: pharmaceutical research and development-related business and cancer precision medicine-related business. - FY2020-Q2RestatedAnnual report
「The operating results by segment are as follows.」
Disclosure continues to be presented across two reportable segments: pharmaceutical research and development-related business and cancer precision medicine-related business. - FY2020-Q1RestatedAnnual report
「The operating results by segment are as follows.」
Disclosure continues to be presented across two reportable segments: pharmaceutical research and development-related business and cancer precision medicine-related business. - FY2018ReframedAnnual report
「During the consolidated fiscal year, we established Cancer Precision Medicine Co., Ltd. (CPM), which operates a cancer precision medicine-related business. We transferred to CPM, through a company split (simplified split), the Tumor Immunology Analysis Department, which was one of our business divisions and conducts research and development into cancer immunotherapy and, as an advanced initiative, T-cell/B-cell receptor analysis services using next-generation sequencers. To provide more appropriate management information, we changed the presentation method to disclose two reportable segments: “pharmaceutical research and development and related businesses” and “cancer precision medicine-related business.”」
The structure changed from the former single segment to two reportable segments: pharmaceutical research and development and cancer precision medicine-related business. - FY2018-Q3RestatedAnnual report
「Our company and its consolidated subsidiaries operate a single business, and their segment is pharmaceutical research and development. Accordingly, segment information is not presented.」
The single-business, single-segment structure relating to pharmaceutical research and development is reiterated. - FY2018-Q2RestatedAnnual report
「Our company and its consolidated subsidiaries operate a single business, and their segment is pharmaceutical research and development. Accordingly, segment information is not presented.」
The single-business, single-segment structure relating to pharmaceutical research and development is reiterated. - FY2017RestatedAnnual report
「Our company and its consolidated subsidiaries engage in pharmaceutical research and development and related businesses. As the business is classified as a single segment, segment information is omitted.」
The single-business, single-segment structure relating to pharmaceutical research and development is reiterated. - FY2017-Q3First statedAnnual report
「Our company and its consolidated subsidiaries operate a single business, and their segment is pharmaceutical research and development. Accordingly, segment information is not presented.」
The disclosure states that our group consists of a single business and single segment relating to pharmaceutical research and development.